Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-27072

Mouridsen, H; Giobbie-Hurder, A; Goldhirsch, A; Thürlimann, B; Paridaens, R; Smith, I; Mauriac, L; Forbes, J F; Price, K N; Regan, M M; Gelber, R D; Coates, A S (2009). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New England Journal of Medicine, 361(8):766-776.

[img]
Preview
PDF
1499Kb

Abstract

BACKGROUND: The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-free survival among postmenopausal women with receptor-positive early breast cancer. It is unknown whether sequential treatment with tamoxifen and letrozole is superior to letrozole therapy alone. METHODS: In this randomized, phase 3, double-blind trial of the treatment of hormone-receptor-positive breast cancer in postmenopausal women, we randomly assigned women to receive 5 years of tamoxifen monotherapy, 5 years of letrozole monotherapy, or 2 years of treatment with one agent followed by 3 years of treatment with the other. We compared the sequential treatments with letrozole monotherapy among 6182 women and also report a protocol-specified updated analysis of letrozole versus tamoxifen monotherapy in 4922 women. RESULTS: At a median follow-up of 71 months after randomization, disease-free survival was not significantly improved with either sequential treatment as compared with letrozole alone (hazard ratio for tamoxifen followed by letrozole, 1.05; 99% confidence interval [CI], 0.84 to 1.32; hazard ratio for letrozole followed by tamoxifen, 0.96; 99% CI, 0.76 to 1.21). There were more early relapses among women who were assigned to tamoxifen followed by letrozole than among those who were assigned to letrozole alone. The updated analysis of monotherapy showed that there was a nonsignificant difference in overall survival between women assigned to treatment with letrozole and those assigned to treatment with tamoxifen (hazard ratio for letrozole, 0.87; 95% CI, 0.75 to 1.02; P=0.08). The rate of adverse events was as expected on the basis of previous reports of letrozole and tamoxifen therapy. CONCLUSIONS: Among postmenopausal women with endocrine-responsive breast cancer, sequential treatment with letrozole and tamoxifen, as compared with letrozole monotherapy, did not improve disease-free survival. The difference in overall survival with letrozole monotherapy and tamoxifen monotherapy was not statistically significant.

Contributors:Moch, H, Varga, Z, Caduff, R, Fink, D
Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology
DDC:610 Medicine & health
Language:English
Date:2009
Deposited On:11 Jan 2010 13:45
Last Modified:23 Nov 2012 14:45
Publisher:Massachusetts Medical Society
ISSN:0028-4793
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:10.1056/NEJMoa0810818
PubMed ID:19692688
Citations:Google Scholar™

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page